Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 25 March 2014 | By Alexander Gaffney, RAC,
A new bill introduced in the US House of Representatives on 24 March 2014 would grant companies additional patent protections for repurposed biological products.
The bill, the Independent Innovator and Repurposing Act (IIRA), is cosponsored by Reps. Joaquin Castro (D-TX) and Randy Forbes (R-VA) and is intended to provide "appropriate intellectual property protections" for some products.
Those products, the bill explains, are any biologicals regulated under Section 351(i)(1) of the Public Health Service Act:
a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.
At its core, the bill would allow sponsors of biological products to apply for an extension of the term of their original patent for an additional five years if the product was approved for a new use, and the sponsor is not affiliated with (or the same as) the original sponsor of the product.
The intent, the legislation says, is to incentivize research and development for new treatments and cures by repurposing already-approved drugs.
This approach is already being advanced within industry and government, as companies share their compound libraries with one another and work with the National Center for Advancing Translational Science (NCATS) to screen potentially useful compounds.
But where Castro and Forbes' bill would differ is in its focus on already-approved products-not discarded ones.
While the bill would apply to all future products, it would also be retroactive to all products approved in the last 10 years that meet its terms.
Tags: House, Latest News, Patent, Bill, Congress, Biologics
Regulatory Focus newsletters
All the biggest regulatory news and happenings.